Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Livzon Pharmaceutical Group Yönetim

Yönetim kriter kontrolleri 4/4

Livzon Pharmaceutical Group's CEO'su Yanggang Tang, Dec2018 tarihinde atandı, in görev süresi 5.83 yıldır. in toplam yıllık tazminatı CN¥ 581.00K olup, şirket hissesi ve opsiyonları dahil olmak üzere 19.1% maaş ve 80.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.038% ine doğrudan sahiptir ve bu hisseler CN¥ 12.42M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 10.3 yıl ve 5.3 yıldır.

Anahtar bilgiler

Yanggang Tang

İcra Kurulu Başkanı

CN¥581.0k

Toplam tazminat

CEO maaş yüzdesi	19.1%
CEO görev süresi	5.8yrs
CEO sahipliği	0.04%
Yönetim ortalama görev süresi	10.3yrs
Yönetim Kurulu ortalama görev süresi	6.5yrs

Son yönetim güncellemeleri

We Think The Compensation For Livzon Pharmaceutical Group Inc.'s (SZSE:000513) CEO Looks About Right

Jun 07

Recent updates

We Think You Can Look Beyond Livzon Pharmaceutical Group's (SZSE:000513) Lackluster Earnings

Aug 30

Livzon Pharmaceutical Group Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 26

A Look At The Fair Value Of Livzon Pharmaceutical Group Inc. (SZSE:000513)

Aug 09

Livzon Pharmaceutical Group (SZSE:000513) Is Paying Out Less In Dividends Than Last Year

Jul 02

We Think The Compensation For Livzon Pharmaceutical Group Inc.'s (SZSE:000513) CEO Looks About Right

Jun 07

Livzon Pharmaceutical Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Apr 26

Does Livzon Pharmaceutical Group (SZSE:000513) Have A Healthy Balance Sheet?

Apr 21

Is Now The Time To Put Livzon Pharmaceutical Group (SZSE:000513) On Your Watchlist?

Mar 15

CEO Tazminat Analizi

Yanggang Tang'un ücretlendirmesi Livzon Pharmaceutical Group'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	CN¥2b
Mar 31 2024	n/a	n/a	CN¥2b
Dec 31 2023	CN¥581k	CN¥111k	CN¥2b
Sep 30 2023	n/a	n/a	CN¥2b
Jun 30 2023	n/a	n/a	CN¥2b
Mar 31 2023	n/a	n/a	CN¥2b
Dec 31 2022	CN¥520k	n/a	CN¥2b
Sep 30 2022	n/a	n/a	CN¥2b
Jun 30 2022	n/a	n/a	CN¥2b
Mar 31 2022	n/a	n/a	CN¥2b
Jan 01 2022	n/a	n/a	CN¥2b
Sep 30 2021	n/a	n/a	CN¥2b
Jun 30 2021	n/a	n/a	CN¥2b
Mar 31 2021	n/a	n/a	CN¥2b
Jan 01 2021	n/a	n/a	CN¥2b
Sep 30 2020	n/a	n/a	CN¥2b
Jun 30 2020	n/a	n/a	CN¥2b
Mar 31 2020	n/a	n/a	CN¥1b
Jan 01 2020	n/a	n/a	CN¥1b
Sep 30 2019	n/a	n/a	CN¥1b
Jun 30 2019	n/a	n/a	CN¥1b
Mar 31 2019	n/a	n/a	CN¥1b
Dec 31 2018	CN¥3m	CN¥800k	CN¥1b

Tazminat ve Piyasa: Yanggang 'nin toplam tazminatı ($USD 82.64K ), CN pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 214.50K ).

Tazminat ve Kazançlar: Yanggang 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Yanggang Tang (54 yo)

5.8yrs

Görev süresi

CN¥581,000

Tazminat

Mr. Yanggang Tang has been President of Livzon Pharmaceutical Group since December 28, 2018 and serves as its Executive Director since February 14, 2019 and served as its Executive Vice President from July...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yanggang Tang	President & Executive Director	5.8yrs	CN¥581.00k	0.038% CN¥ 11.8m
Guoxiang Xu	Executive Vice Chairman & VP of Sales	7.3yrs	CN¥547.19k	0.086% CN¥ 26.8m
Yanxia Si	VP & CFO	10.3yrs	CN¥354.39k	0.044% CN¥ 13.8m
Liang Yang	VP, Secretary to the Board & Company Secretary	10.3yrs	CN¥235.72k	0.022% CN¥ 6.9m
Daihong Yang	Vice President	18.4yrs	CN¥371.99k	0.051% CN¥ 16.0m
Yuxuan Huang	Vice President	6yrs	CN¥239.24k	0.015% CN¥ 4.6m
Jun Du	Vice President	1.1yrs	CN¥516.55k	0.0055% CN¥ 1.7m
Jianing Liu	Chief Investment Officer & Head of BD Dept.	no data	Veri yok	Veri yok
Jianying Zhuang	Head of Accounting Department	no data	Veri yok	Veri yok
Maolin Wang	Chief Supervisor and GM of Legal & Compliance	23.8yrs	CN¥353.10k	Veri yok
Daping Liu	Vice President	less than a year	Veri yok	Veri yok

10.3yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: 000513 'un yönetim ekibi deneyimli ve deneyimlidir ( 10.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yanggang Tang	President & Executive Director	5.7yrs	CN¥581.00k	0.038% CN¥ 11.8m
Guoxiang Xu	Executive Vice Chairman & VP of Sales	7.3yrs	CN¥547.19k	0.086% CN¥ 26.8m
Maolin Wang	Chief Supervisor and GM of Legal & Compliance	14.8yrs	CN¥353.10k	Veri yok
Qingfeng Qiu	Non-Executive Director	17.5yrs	CN¥9.60k	Veri yok
Baoguo Zhu	Non-Executive Chairman of the Board	22.3yrs	CN¥325.00k	Veri yok
Desheng Tao	Non-Executive Vice Chairman	15.3yrs	CN¥300.00k	0.096% CN¥ 30.1m
Qiusheng Tian	Independent Non-Executive Director	5yrs	CN¥12.00k	Veri yok
Hua Bai	Independent Non-Executive Director	4.3yrs	CN¥12.00k	Veri yok
Huamin Huang	Supervisor	11.3yrs	CN¥36.00k	Veri yok
Huiyuan Luo	Independent Non-Executive Director	3.3yrs	CN¥12.00k	Veri yok
Kam Wa Wong	Independent Non-Executive Director	5yrs	CN¥12.00k	Veri yok
Lijie Cui	Independent Non-Executive Director	3.3yrs	CN¥12.00k	Veri yok

6.5yrs

Ortalama Görev Süresi

56.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 000513 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.3 yıldır).

Livzon Pharmaceutical Group Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Livzon Pharmaceutical Group Inc. Announces Resignation of Yu Xiong as Director

We Think The Compensation For Livzon Pharmaceutical Group Inc.'s (SZSE:000513) CEO Looks About Right

Livzon Pharmaceutical Group Inc., Annual General Meeting, Jun 14, 2024

Livzon Pharmaceutical Group Inc. Announces Board Appointments

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Shanghai Livzon Pharmaceutical Manufacturing Co., Ltd. Receives the Approval Notice for Supplementary Application for Drug

Livzon Pharmaceutical Group Inc. Announces Resignation of Yu Xiong as Director

Livzon Pharmaceutical Group Inc. to Report Q3, 2024 Results on Oct 24, 2024

Investor sentiment improves as stock rises 16%

We Think You Can Look Beyond Livzon Pharmaceutical Group's (SZSE:000513) Lackluster Earnings

Livzon Pharmaceutical Group Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 21% undervalued after recent price drop

A Look At The Fair Value Of Livzon Pharmaceutical Group Inc. (SZSE:000513)

Now 21% undervalued after recent price drop

Livzon Pharmaceutical Group (SZSE:000513) Is Paying Out Less In Dividends Than Last Year

Dividend reduced to CN¥1.35

Livzon Pharmaceutical Group Inc. to Report First Half, 2024 Results on Aug 23, 2024

We Think The Compensation For Livzon Pharmaceutical Group Inc.'s (SZSE:000513) CEO Looks About Right

Livzon Pharmaceutical Group Inc., Annual General Meeting, Jun 14, 2024

Livzon Pharmaceutical Factory Receives Approval for the U.S. FDA Approval for the Company's Drug Cetrorelix Acetate for Injection

Livzon Pharmaceutical Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Does Livzon Pharmaceutical Group (SZSE:000513) Have A Healthy Balance Sheet?

Livzon Pharmaceutical Group Inc. to Report Q1, 2024 Results on Apr 24, 2024

Full year 2023 earnings: Revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 05 August 2024

Is Now The Time To Put Livzon Pharmaceutical Group (SZSE:000513) On Your Watchlist?

Livzon Pharmaceutical Group Inc. to Report Fiscal Year 2023 Results on Mar 29, 2024

Livzon MABPharm Inc. Announces the Inclusion of Recombinant SARS-COV-2 Bivalent (Original/Omicron XBB) Fusion Protein Vaccine (Cho Cell) for Emergency Use

Livzon Pharmaceutical Group Inc. (SZSE:000513) announces an Equity Buyback for CNY 600 million worth of its shares.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. and Shanghai Livzon Pharmaceutical Manufacturing Co., Ltd. Receives Acceptance of the Application for the Registration and Marketing Authorization of Triptorelin Acetate Microspheres for Injection

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. Announces Board Appointments

Livzon Pharmaceutical Group Inc. Announces the Final Cash Dividend (A Shares) (Tax Included) for 2022, Payable on 04 July 2023

Livzon Pharmaceutical Group Inc. Approves Final Cash Dividend for the Year Ended 31 December 2022, Payable on 31 July 2023

Full year 2022 earnings: Revenues in line with analyst expectations

Livzon Pharmaceutical Group Inc. Announces Approval of Drug Marketing Authorisation Submitted by Livzon MABPharm Inc. for the Tocilizumab Injection Atvtia

Now 20% undervalued

Less than half of directors are independent

Third quarter 2022 earnings: Revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. to Report Nine Months, 2022 Results on Oct 25, 2022

Price target decreased to CN¥42.19

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. Receives Approval Notice for Supplementary Application for Drug

Livzon Pharmaceutical Group Inc. to Report First Half, 2022 Results on Aug 09, 2022

Livzon Pharmaceutical Announces on Drug Passing Consistency Evaluation for Generics

Livzon Pharmaceutical Group Inc. Approves Cash Dividend for 2021

Less than half of directors are independent

Livzon Pharmaceutical Group Inc., Annual General Meeting, May 20, 2022

Livzon Pharmaceutical Group Inc. Proposes Final Dividend for the Year Ended 31 December 2021, Payable on June 24, 2022

Livzon Pharmaceutical Group Inc. to Report Q1, 2022 Results on Apr 21, 2022

Full year 2021 earnings: EPS misses analyst expectations

Livzon Pharmaceutical Group Inc. Announces Ordinary Final Dividend for the Year Ended December 31, 2021, Payable on June 24, 2022

Investor sentiment improved over the past week

Livzon Pharmaceutical Group Inc. Obtains Approval Notice for Clinical Trial on Drug from National Medical Products Administration

Third quarter 2021 earnings released: EPS CN¥0.41 (vs CN¥0.44 in 3Q 2020)

Non-Executive Vice Chairman exercised options to buy CN¥239k worth of stock.

Livzon Pharmaceutical Group Inc. Announces Approval Notice for Clinical Trial on A Drug

Non-Executive Vice Chairman exercised options to buy CN¥408k worth of stock.

Second quarter 2021 earnings released: EPS CN¥0.58 (vs CN¥0.64 in 2Q 2020)

Independent Non-Executive Director Zhihua Zheng has left the company

Independent Non-Executive Director Yun Xie has left the company

Livzon Pharmaceutical Group Inc. Approves Cash Dividend for 2020, Payable on or Before June 25, 2021

Livzon Pharmaceutical Group Inc. (SZSE:000513) completed the acquisition of share transfer agreement to acquire a 40% stake in Tianjin Tongrentang Group Co., Ltd. from Tianjin Tasly Healthcare Industry Investment Partnership.

New 90-day low: CN¥34.73

Livzon Pharmaceutical Group Inc. to Report Fiscal Year 2020 Results on Mar 23, 2021

Investor sentiment deteriorated over the past week

New 90-day low: CN¥38.49

Livzon Pharmaceutical Group Inc. announced that it expects to receive CNY 961.6 million in funding from YF Pharmab Limited

New 90-day low: CN¥42.15

President & Executive Director exercised options to buy CN¥2.7m worth of stock.

New 90-day low: CN¥46.34

Third quarter earnings released